Objective:

To explore the evolving demands on diagnostics as antibody-drug conjugates (ADCs) expand across tumor types and the implications for biomarker assessment.

Approach:

Key Findings:

• The oncology companion diagnostics market is projected to reach $8.4 billion by 2030.
• Recent regulatory approvals of new ADCs have catalyzed growth in the field.
• ADCs can remain effective even with low protein expression.
• IHC has limitations in dynamic range and sensitivity.
• Computational pathology offers capabilities that improve accuracy and consistency in biomarker assessments.

Interpretation:

Accurate biomarker assessment is critical for the effective use of ADCs, especially as they target proteins rather than genomic alterations.

Limitations:

• Traditional IHC scoring systems may not adequately assess low biomarker expression.
• Human eye assessments can struggle with distinguishing true biomarker staining at low levels.

Conclusion:

The integration of advanced diagnostic technologies is essential for optimizing patient access to ADC therapies.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.